Raffaella De Pace

Raffaella De Pace

Auto-generated profile, based on publicly available information

Raffaella De Pace

Division of Neuroscience and Cellular Structure, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
WWWei Wu
Wei Wu
SKSarah E. Kargbo-Hill
Sarah E. Kargbo-Hill
WNWilliam J. Nathan
William J. Nathan
JPJacob Paiano
Jacob Paiano
ECElsa Callen
Elsa Callen
ANAndré Nussenzweig
André Nussenzweig

10 April 2024 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
RPRaffaella De Pace
Raffaella De Pace
SGSaikat Ghosh
Saikat Ghosh
VRVeronica H. Ryan
Veronica H. Ryan
MSMira Sohn
Mira Sohn
MJMichal Jarnik
Michal Jarnik
JBJuan S. Bonifacino
Juan S. Bonifacino
In neurons, RNA granules are transported along the axon for local translation away from the soma. Recent studies indicate that some of this transport involves hitchhiking of RNA granules on lysosome-related vesicles. In the present study, we leveraged the ability to prevent transport of these vesicles into the axon by knockout of the lysosome–kinesin adaptor BLOC-one-related complex (BORC) to identify a subset of axonal mRNAs that depend on lysosome-related vesicles for transport. We found that BORC knockout causes depletion of a large group of axonal mRNAs mainly encoding ribosomal and mitochondrial/oxidative phosphorylation proteins. This depletion results in mitochondrial defects and eventually leads to axonal degeneration in human induced pluripotent stem cell (iPSC)-derived and mouse neurons. Pathway analyses of the depleted mRNAs revealed a mechanistic connection of BORC deficiency with common neurodegenerative disorders. These results demonstrate that mRNA transport on lysosome-related vesicles is critical for the maintenance of axonal homeostasis and that its failure causes axonal degeneration.

19 November 2019 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JBJillian Belgrad
Jillian Belgrad
RPRaffaella De Pace
Raffaella De Pace
RFR. Douglas Field
R. Douglas Field
Autophagy is the cellular process involved in transportation and degradation of membrane, proteins, pathogens, and organelles. This fundamental cellular process is vital in development, plasticity, and response to disease and injury. Compared with neurons, little information is available on autophagy in glia, but it is paramount for glia to perform their critical responses to nervous system disease and injury, including active tissue remodeling and phagocytosis. In myelinating glia, autophagy has expanded roles, particularly in phagocytosis of mature myelin and in generating the vast amounts of membrane proteins and lipids that must be transported to form new myelin. Notably, autophagy plays important roles in removing excess cytoplasm to promote myelin compaction and development of oligodendrocytes, as well as in remyelination by Schwann cells after nerve trauma. This review summarizes the cell biology of autophagy, detailing the major pathways and proteins involved, as well as the roles of autophagy in Schwann cells and oligodendrocytes in development, plasticity, and diseases in which myelin is affected. This includes traumatic brain injury, Alexander's disease, Alzheimer's disease, hypoxia, multiple sclerosis, hereditary spastic paraplegia, and others. Promising areas for future research are highlighted.

15 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
XCXin Chen
Xin Chen
TDThomas Dong
Thomas Dong
YHYuhui Hu
Yuhui Hu
RPRaffaella De Pace
Raffaella De Pace
RMRafael Mattera
Rafael Mattera
SGSteven J. Gray
Steven J. Gray
Spastic paraplegia 50 (SPG50) is an ultrarare childhood-onset neurological disorder caused by biallelic loss-of-function variants in the AP4M1 gene. SPG50 is characterized by progressive spastic paraplegia, global developmental delay, and subsequent intellectual disability, secondary microcephaly, and epilepsy. We preformed preclinical studies evaluating an adeno-associated virus (AAV)/AP4M1 gene therapy for SPG50 and describe in vitro studies that demonstrate transduction of patient-derived fibroblasts with AAV2/AP4M1, resulting in phenotypic rescue. To evaluate efficacy in vivo, Ap4m1-KO mice were intrathecally (i.t.) injected with 5 × 1011, 2.5 × 1011, or 1.25 × 1011 vector genome (vg) doses of AAV9/AP4M1 at P7–P10 or P90. Age- and dose-dependent effects were observed, with early intervention and higher doses achieving the best therapeutic benefits. In parallel, three toxicology studies in WT mice, rats, and nonhuman primates (NHPs) demonstrated that AAV9/AP4M1 had an acceptable safety profile up to a target human dose of 1 × 1015 vg. Of note, similar degrees of minimal-to-mild dorsal root ganglia (DRG) toxicity were observed in both rats and NHPs, supporting the use of rats to monitor DRG toxicity in future i.t. AAV studies. These preclinical results identify an acceptably safe and efficacious dose of i.t.-administered AAV9/AP4M1, supporting an investigational gene transfer clinical trial to treat SPG50.

25 December 2013 in Human Mutation
Verified
Journal Article
Open access
PDF file
RPRaffaella De Pace
Raffaella De Pace
Maria Francisca CoutinhoMaria Francisca Coutinho
Maria Francisca Coutinho
FKFriedrich Koch-Nolte
Friedrich Koch-Nolte
Friedrich HaagFriedrich Haag
Friedrich Haag
MPMaria João Prata
Maria João Prata
SPSandra Pohl
Sandra Pohl
Mucolipidosis (ML) II and MLIII alpha/beta are two pediatric lysosomal storage disorders caused by mutations in the GNPTAB gene, which encodes an α/β-subunit precursor protein of GlcNAc-1-phosphotransferase. Considerable variations in the onset and severity of the clinical phenotype in these diseases are observed. We report here on expression studies of two missense mutations c.242G>T (p.Trp81Leu) and c.2956C>T (p.Arg986Cys) and two frameshift mutations c.3503_3504delTC (p.Leu1168GlnfsX5) and c.3145insC (p.Gly1049ArgfsX16) present in severely affected MLII patients, as well as two missense mutations c.1196C>T (p.Ser399Phe) and c.3707A>T (p.Lys1236Met) reported in more mild affected individuals. We generated a novel α-subunit-specific monoclonal antibody, allowing the analysis of the expression, subcellular localization, and proteolytic activation of wild-type and mutant α/β-subunit precursor proteins by Western blotting and immunofluorescence microscopy. In general, we found that both missense and frameshift mutations that are associated with a severe clinical phenotype cause retention of the encoded protein in the endoplasmic reticulum and failure to cleave the α/β-subunit precursor protein are associated with a severe clinical phenotype with the exception of p.Ser399Phe found in MLIII alpha/beta. Our data provide new insights into structural requirements for localization and activity of GlcNAc-1-phosphotransferase that may help to explain the clinical phenotype of MLII patients.

17 May 2019 in PLOS Biology
Verified
Journal Article
Open access
PDF file
CGCarlos Guardia
Carlos Guardia
RPRaffaella De Pace
Raffaella De Pace
ASAritra Sen
Aritra Sen
ASAmra Saric
Amra Saric
MJMichal Jarnik
Michal Jarnik
JBJuan S. Bonifacino
Juan S. Bonifacino
We report the development and characterization of a method, named reversible association with motor proteins (RAMP), for manipulation of organelle positioning within the cytoplasm. RAMP consists of coexpressing in cultured cells (i) an organellar protein fused to the streptavidin-binding peptide (SBP) and (ii) motor, neck, and coiled-coil domains from a plus-end–directed or minus-end–directed kinesin fused to streptavidin. The SBP–streptavidin interaction drives accumulation of organelles at the plus or minus end of microtubules, respectively. Importantly, competition of the streptavidin–SBP interaction by the addition of biotin to the culture medium rapidly dissociates the motor construct from the organelle, allowing restoration of normal patterns of organelle transport and distribution. A distinctive feature of this method is that organelles initially accumulate at either end of the microtubule network in the initial state and are subsequently released from this accumulation, allowing analyses of the movement of a synchronized population of organelles by endogenous motors. Intracellular organelles are dynamically distributed throughout the cytoplasm by virtue of regulated interactions with microtubule motors. A significant development over the past few years has been the realization that the spatial distribution of organelles influences their functions. However, in most cases, the exact relationship between organelle dynamics and function is not well-understood. Investigating this relationship requires methods to experimentally manipulate organelle dynamics. In this article, we describe a novel, to our knowledge, method to reposition organelles within the cytoplasm by artificial coupling to microtubule motor domains. This method, named reversible association with motor proteins (RAMP), consists of coexpressing an organellar protein appended with a streptavidin-binding peptide and an anterograde or retrograde motor domain fused to streptavidin. Interaction of the streptavidin-binding peptide with streptavidin results in coupling of the organelle to the motor, leading to redistribution of the organelle to the periphery or the center of the cell, respectively. Importantly, this redistribution can be reversed by the addition of the vitamin biotin, which competes off the streptavidin-binding peptide–streptavidin interaction. We show that this method is applicable to various organelles, including lysosomes, mitochondria, endoplasmic reticulum, and peroxisomes, enabling future studies of the properties of these organelles at different cellular locations.